Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

Evorpacept improved tumor response in patients with HER2-positive gastric/GEJ cancer, becoming the first ... TRP to an assumed RP control ORR of 30% Secondary endpoints of PFS and OS were immature ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

We anticipate achieving several additional clinical milestones in the near-term that could advance evorpacept towards being a best-in-class, combinable therapeutic across a wide range of cancer types ...

Overall survival (OS) data, a secondary ... Cancer Institute on Unsplash. Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as ...

Other innovative medicines like Nexviazyme, Rezurock, and Sarclisa continue to perform ... based on alpha-emitting isotopes for rare cancers. We will keep you updated as we continue to access ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment ... it can be accessed via the Cancer Drugs Fund – but covered ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...